Alzheimer’s Disease

What Is Alzheimer’s Disease?

Alzheimer’s disease is a progressive neurodegenerative condition characterized by two distinctive brain changes, abnormal clumps of a protein called amyloid beta that accumulate outside brain cells, and twisted tangles of another protein called tau that form inside them.¹

These two protein abnormalities follow somewhat different patterns of spread throughout the brain, with tau pathology typically beginning in structures involved in memory formation, while amyloid pathology tends to first accumulate within the outer layer of the brain responsible for higher level thinking.¹

Research suggests these two processes interact with one another over the course of the disease, with evidence indicating that once amyloid buildup reaches a certain threshold, tau pathology begins spreading more rapidly throughout the brain, contributing to the disease’s progressive nature.²

Alzheimer’s disease is characterized by two cardinal pathologies, extracellular accumulation of amyloid related aggregates and intracellular formation of tau related neurofibrillary tangles, both of which disrupt normal neuronal function.
National Center for Biotechnology Information

Symptoms

Alzheimer’s disease produces progressive, irreversible cognitive impairment and memory loss, with early stages often presenting as mild cognitive impairment before more pronounced decline develops.¹

As the disease advances through its middle and later stages, cognitive decline becomes increasingly pronounced, affecting memory, language abilities, and executive functioning in ways that progressively interfere with daily independence.¹

This clinical progression closely mirrors the underlying spread of tau pathology through the brain, beginning in structures involved in memory, extending into broader limbic structures, and eventually affecting the outer brain regions responsible for complex thought in the most advanced disease stages.¹

Causes

Genetic mutations affecting specific proteins involved in amyloid production cause rare, early onset familial forms of Alzheimer’s disease, though these inherited mutations account for only a small fraction of overall cases.²

For the more common, later onset form of the disease, a specific genetic variant called apolipoprotein E4 represents the strongest known genetic risk factor, though complex interactions between multiple genes and environmental factors also contribute to individual risk.²

At the cellular level, abnormal tau protein detaches from its normal supportive role within neurons, causing structural breakdown of the cell’s internal skeleton and ultimately forming the characteristic tangles that damage and eventually kill affected brain cells.¹

Risk Factors

Carrying one or two copies of the apolipoprotein E4 gene variant substantially raises Alzheimer’s disease risk, with people carrying two copies facing particularly elevated risk compared to those with only one copy or none.³

Beyond genetic risk, several acquired, modifiable health conditions have been linked to increased Alzheimer’s disease risk, including high blood pressure, abnormal cholesterol, cerebrovascular disease, type two diabetes, and obesity.²

Certain medication classes, including anticholinergic drugs and proton pump inhibitors, have also been associated with elevated Alzheimer’s disease risk, adding another dimension to the modifiable factors potentially relevant to long term brain health.²

Complications

As Alzheimer’s disease progresses, neurons throughout affected brain regions become injured and eventually die, causing connections between brain networks to break down and specific brain regions to shrink measurably over time.¹

By the most advanced disease stages, this process of brain volume loss becomes widespread, reflecting the cumulative impact of significant, ongoing cell death throughout multiple brain regions.¹

For patients treated with newer anti-amyloid therapies, a specific safety concern called amyloid related imaging abnormalities represents an important potential complication, occurring more frequently among people who carry two copies of the apolipoprotein E4 gene variant.⁴

Treatment

Anti-amyloid monoclonal antibody therapies, including lecanemab and donanemab, work by directly targeting and helping clear amyloid protein from the brain, and clinical trials have shown these treatments produce robust amyloid clearance alongside modest slowing of cognitive decline in early symptomatic disease.⁴

Interestingly, research suggests that people carrying the apolipoprotein E4 variant may respond equally well or even somewhat better to these amyloid targeting treatments compared to people without this genetic variant, despite also facing higher treatment related safety risk.⁵

Because people who carry two copies of the apolipoprotein E4 variant face meaningfully higher risk of treatment related brain imaging abnormalities, some regulatory bodies have specifically restricted use of certain anti-amyloid therapies in this particular genetic subgroup, reflecting an evolving, more individualized approach to treatment selection.⁴

Prevention

While genetic risk factors such as apolipoprotein E4 status cannot be modified, addressing acquired, modifiable risk factors, including blood pressure, cholesterol, and diabetes management, may help reduce overall Alzheimer’s disease risk.²

Genetic testing for apolipoprotein E4 status has become increasingly relevant not only for risk assessment but also for guiding treatment decisions, given the meaningful differences in both treatment response and safety risk associated with this genetic variant.⁵

Ongoing research continues to refine strategies for maximizing the benefit of anti-amyloid treatments while more carefully managing associated risks, reflecting the field’s continued evolution toward more precise, individualized patient selection.⁴

Why Visual Communication Matters for Alzheimer’s Disease

Explaining how two distinct abnormal proteins interact over years to progressively damage the brain requires visuals that make this complex, gradual disease process concrete and understandable for patients and families facing a difficult diagnosis.

Pharmaceutical companies, neurology practices, and patient education organizations rely on clear illustration and animation to explain Alzheimer’s disease biology and support informed treatment decisions.

• Illustrating amyloid plaque and tau tangle formation within the brain
• Animating the spread of pathology through different brain regions over time
• Explaining the mechanism of action of anti-amyloid monoclonal antibody therapy
• Visualizing the role of genetic testing in treatment selection and risk assessment
• Supporting patient education on modifiable risk factors and prevention
• Creating training materials for neurology and primary care clinicians

How Biotic Artlab Supports Alzheimer’s Disease Communication

We work with pharmaceutical companies, neurology practices, and patient advocacy organizations to create scientifically accurate visuals that make Alzheimer’s disease and its treatment easier to understand.

• Custom 3D animations of amyloid and tau pathology development
• Detailed illustrations of anti-amyloid monoclonal antibody mechanism of action
• Patient facing materials on genetic risk, testing, and treatment selection
• Educational content addressing modifiable risk factors for brain health
• Clinical training materials for neurology and primary care teams
• Conference presentations and marketing visuals for brain health audiences

Frequently Asked Questions

What causes Alzheimer’s disease?

The disease involves accumulation of amyloid protein outside brain cells and tau protein tangles inside them, driven by a combination of genetic and acquired risk factors.¹

What is APOE4?

APOE4 is a genetic variant representing the strongest known risk factor for late onset Alzheimer’s disease, also influencing treatment response and safety risk.³

How do anti-amyloid treatments work?

Medications such as lecanemab and donanemab work by clearing amyloid protein from the brain, modestly slowing cognitive decline in early symptomatic disease.⁴

Are anti-amyloid treatments safe for everyone?

People who carry two copies of the APOE4 gene variant face higher risk of treatment related brain imaging abnormalities, leading some regulators to restrict use in this group.⁴

Can Alzheimer’s disease risk be reduced?

While genetic risk cannot be changed, managing modifiable factors such as blood pressure, cholesterol, and diabetes may help reduce overall risk.²

Is Alzheimer’s disease always inherited?

No, inherited genetic mutations cause only a small fraction of cases, primarily early onset familial disease, while most cases involve complex genetic and environmental factors.²

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to Alzheimer’s disease or brain health, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Institute on Aging. What Happens to the Brain in Alzheimer’s Disease.
2. National Center for Biotechnology Information. Alzheimer’s Disease, Etiology, Neuropathology and Pathogenesis.
3. National Center for Biotechnology Information. Lecanemab Therapy and APOE Genotype.
4. National Center for Biotechnology Information. Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease, Evidence, ARIA Risk, and Precision Patient Selection.
5. National Center for Biotechnology Information. Clinical Efficacy of Anti-Amyloid Antibodies in Apolipoprotein E4 Homozygotes.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, emergency care, or individualized advice from a qualified healthcare professional.